Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
+$0.01 today
- Market cap
- $113.54M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
Volume 7.09M
Average 4.03M
Dividends
Akebia Therapeutics, Inc. dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does Akebia Therapeutics, Inc. compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
KalVista Pharmaceuticals, Inc. NASDAQ:KALV | $1.44B | 0.00% | $0.00 | 0.00% | 0.00% |
Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | $897.52M | 0.00% | $0.00 | 0.00% | 0.00% |
Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | $837.18M | 0.00% | $0.00 | 0.00% | 0.47% |
4D Molecular Therapeutics, Inc. NASDAQ:FDMT | $675.64M | 0.00% | $0.00 | 0.00% | 0.00% |
Olema Pharmaceuticals, Inc. NASDAQ:OLMA | $662.30M | 0.00% | $0.00 | 0.00% | 0.00% |
Zevra Therapeutics, Inc. NASDAQ:ZVRA | $540.30M | 0.00% | $0.00 | 0.00% | 0.00% |
Prothena Corporation plc NASDAQ:PRTA | $419.01M | 0.00% | $0.00 | 0.00% | 1.64% |
Compass Therapeutics, Inc. NASDAQ:CMPX | $139.35M | 0.00% | $0.00 | 0.00% | 0.00% |
Gossamer Bio, Inc. NASDAQ:GOSS | $67.10M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about AKBA's dividend, answered from reported figures.
Does AKBA stock pay dividends?
Akebia Therapeutics, Inc. (AKBA) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is AKBA's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.